Lang Qingata

PreclinicalSmall molecule

Lang Qingata is one of 51 small molecule programs targeting Non-Alcoholic Steatohepatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic SteatohepatitisActive, not recruiting

Non-Alcoholic SteatohepatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

96 competitors in Non-Alcoholic Steatohepatitis

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

4 2

Victoza

Novo Nordisk

Phase 3

2 3

Uloric

Takeda

Phase 2

1 4

Farxiga

AstraZeneca

Phase 2

1 5

Diosmin

TTanta University

Phase 3

1 6

Efruxifermin

Akero Therapeutics

Phase 3

1 7

Dipeptidyl Peptidase 4 Inhibitor

Boehringer Ingelheim

Phase 3

1 8

Metadoxine

AAlcobra Ltd.

Phase 3

1 9

Zetia

OOrganon and Co

Phase 2

2 10

Legalon

BBukwang Pharmaceutical

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar

Recruiting·SShupei Li·N/A·NCT06193629·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lang Qingata. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lang Qingata compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lang Qingata. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shupei Li company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShupei Li

Lang Qingata

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News